BioCentury | Jun 2, 2014
Clinical News

Kiacta eprodisate: Completed Phase III enrollment

...Switzerland to treat AA amyloidosis. Bellus granted exclusive, worldwide rights to Kiacta to Auven (formerly Celtic Therapeutics...
BioCentury | May 12, 2014
Company News

Auven Therapeutics, Icahn School of Medicine at Mount Sinai deal

...Mount Sinai granted private equity firm Auven Therapeutics (formerly Celtic Therapeutics) exclusive, worldwide rights to develop and...
BioCentury | May 5, 2014
Product Development

Targeted cargo

...were transferred to a holding company 75% owned by private equity firm Auven Therapeutics (formerly Celtic Therapeutics...
BioCentury | Dec 9, 2013
Clinical News

Kiacta eprodisate: Phase III ongoing

...granted exclusive, worldwide rights to Kiacta to Celtic Therapeutics Holdings. Bellus Health Inc. (TSX:BLU), Laval, Quebec Celtic Therapeutics...
BioCentury | Oct 21, 2013
Company News

ADC Therapeutics, Spirogen, AstraZeneca deal

...MedImmune and ADC Therapeutics will share costs and profits. Private equity firm Auven Therapeutics (formerly Celtic Therapeutics...
BioCentury | Oct 21, 2013
Strategy

MedImmune's warheads

...be transferred to a holding company 75% owned by private equity firm Auven Therapeutics (formerly Celtic Therapeutics...
BioCentury | Oct 15, 2013
Top Story

AstraZeneca in two ADC deals

...profits. Both Spirogen and ADC Therapeutics were launched by private equity firm Auven Therapeutics (formerly Celtic Therapeutics...
BioCentury | Aug 5, 2013
Clinical News

Kiacta eprodisate regulatory update

...granted exclusive, worldwide rights to Kiacta to Celtic Therapeutics Holdings. Bellus Health Inc. (TSX:BLU), Laval, Quebec Celtic Therapeutics...
BioCentury | Mar 18, 2013
Company News

Auven Therapeutics finance, cancer news

...Private equity firm Celtic Therapeutics Management LLLP changed its name to Auven Therapeutics "to avoid confusion related to other...
...to other Celtic entities." The firm also changed the name of its private equity fund Celtic Therapeutics...
BioCentury | Nov 5, 2012
Finance

Banker tracks

...who previously was SVP and CFO, also joined Safeguard's board. PE tracks Beth Hecht joined Celtic Therapeutics...
Items per page:
1 - 10 of 38
BioCentury | Jun 2, 2014
Clinical News

Kiacta eprodisate: Completed Phase III enrollment

...Switzerland to treat AA amyloidosis. Bellus granted exclusive, worldwide rights to Kiacta to Auven (formerly Celtic Therapeutics...
BioCentury | May 12, 2014
Company News

Auven Therapeutics, Icahn School of Medicine at Mount Sinai deal

...Mount Sinai granted private equity firm Auven Therapeutics (formerly Celtic Therapeutics) exclusive, worldwide rights to develop and...
BioCentury | May 5, 2014
Product Development

Targeted cargo

...were transferred to a holding company 75% owned by private equity firm Auven Therapeutics (formerly Celtic Therapeutics...
BioCentury | Dec 9, 2013
Clinical News

Kiacta eprodisate: Phase III ongoing

...granted exclusive, worldwide rights to Kiacta to Celtic Therapeutics Holdings. Bellus Health Inc. (TSX:BLU), Laval, Quebec Celtic Therapeutics...
BioCentury | Oct 21, 2013
Company News

ADC Therapeutics, Spirogen, AstraZeneca deal

...MedImmune and ADC Therapeutics will share costs and profits. Private equity firm Auven Therapeutics (formerly Celtic Therapeutics...
BioCentury | Oct 21, 2013
Strategy

MedImmune's warheads

...be transferred to a holding company 75% owned by private equity firm Auven Therapeutics (formerly Celtic Therapeutics...
BioCentury | Oct 15, 2013
Top Story

AstraZeneca in two ADC deals

...profits. Both Spirogen and ADC Therapeutics were launched by private equity firm Auven Therapeutics (formerly Celtic Therapeutics...
BioCentury | Aug 5, 2013
Clinical News

Kiacta eprodisate regulatory update

...granted exclusive, worldwide rights to Kiacta to Celtic Therapeutics Holdings. Bellus Health Inc. (TSX:BLU), Laval, Quebec Celtic Therapeutics...
BioCentury | Mar 18, 2013
Company News

Auven Therapeutics finance, cancer news

...Private equity firm Celtic Therapeutics Management LLLP changed its name to Auven Therapeutics "to avoid confusion related to other...
...to other Celtic entities." The firm also changed the name of its private equity fund Celtic Therapeutics...
BioCentury | Nov 5, 2012
Finance

Banker tracks

...who previously was SVP and CFO, also joined Safeguard's board. PE tracks Beth Hecht joined Celtic Therapeutics...
Items per page:
1 - 10 of 38